Introduction
============

Functional dyspepsia (FD) is a common functional gastrointestinal disorder characterized by heterogeneous symptoms thought to originate in the gastroduodenal region, including postprandial fullness, early satiety, and epigastric pain and burning ([@bib1]). FD is further subdivided into two, potentially co-existing, diagnostic categories as follows: (i) postprandial distress syndrome (PDS), characterized by postprandial fullness and early satiation, and (ii) epigastric pain syndrome (EPS), characterized by epigastric pain and burning ([@bib2]). Upon routine diagnostic investigation, FD symptoms appear to lack a structural or metabolic cause to readily explain their presence, making diagnosis, treatment, and the establishment of treatment outcomes difficult ([@bib1]). Although the symptoms of FD overlap with other gastrointestinal disorders, such as gastroesophageal reflux disease, irritable bowel syndrome, and gastroparesis ([@bib1], [@bib2]), FD is considered a distinct disorder with considerable impact on the quality of life of those diagnosed with it ([@bib3]).

Patient assessment is critical in FD, because, lacking a clear organic origin, it is considered a symptom-defined disorder. Although patient-reported outcome (PRO) questionnaires for gastrointestinal disorders exist, including for FD (e.g., Dyspepsia Symptom Severity Index ([@bib4]) and Nepean Dyspepsia Index ([@bib5])), until recently it had been unclear to what extent the development of these existing questionnaires was consistent with the US Food and Drug Administration's (FDA) Guidance for Industry---Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims ([@bib6]) (hereafter referred to as "FDA PRO Guidance") and, therefore, to what extent the questionnaires were suitable for use in regulated clinical trials to evaluate new product treatment claims. Broadly, the FDA PRO Guidance explains that PRO measure development should be informed by rigorous and well-documented qualitative research, in order to ensure that the tool assesses concepts that are (i) relevant to the disease or condition, (ii) important to individuals with the disease or condition, and (iii) understandable to respondents (that is, the patient). In particular, the FDA PRO Guidance assigns a premium to direct patient input toward the development of PRO measures intended for use to support product approval and labeling.

In recognition of the importance of scientifically defensible PRO measures for use in clinical trials, the Critical Path Institute's (C-Path) PRO Consortium ([@bib7]), through its FD Working Group and in conjunction with advisors from the FDA, aimed to make publicly available an FD symptom-focused PRO measure that could be used to support primary endpoints in regulated FD clinical trials and to submit the measure for qualification under the FDA's Drug Development Tool Qualification Program ([@bib8]). As an initial step, the FD Working Group documented the primary symptoms of FD from the literature and evaluated the extent to which existing questionnaires target those symptoms and were defensible for use in regulated clinical trials to assess treatment efficacy claims intended for product labeling ([@bib9]). In this study, a total of 56 articles and 16 instruments assessing FD symptoms were reviewed. Concepts listed in the Rome III criteria for FD (*n*=7), those assessed by existing FD instruments (*n*=34), and symptoms reported by patients in published qualitative research (*n*=6) were summarized in an FD conceptual model (reproduced in [Figure 1](#fig1){ref-type="fig"}). Of note, each of the symptoms described in the published qualitative research reports was also specified in the Rome III criteria, with the exception of vomiting.

With respect to the 16 instruments found in the literature review, three (the Dyspepsia Symptom Severity Index ([@bib4]), Nepean Dyspepsia Index([@bib5]), and Short-Form Nepean Dyspepsia Index ([@bib10])) assessed all seven FD symptoms listed in the Rome III criteria (i.e., early satiation, epigastric burning, postprandial fullness, postprandial nausea, excessive belching, epigastric pain, and upper abdomen bloating). Despite their strong FD symptom coverage (and evidence of patient involvement in development), their potential qualification for use to substantiate product labeling goals was questionable in light of concerns regarding regulatory expectations around specified recall periods and response options ([@bib9]).

Given the conclusion that none of the existing PRO measures assessing all seven FD symptoms listed in the Rome III criteria adhered to the regulatory principles necessary to support product labeling, the FD Working Group initiated the development of a novel tool, the Functional Dyspepsia Symptom Diary (FDSD). The purpose of this study is to describe the research and evidentiary basis that contributed to and supported the development of the FDSD. The specific development activities included the following: (i) identification and documentation of FD symptoms from the patient perspective; (ii) selection of the FD symptom concepts to be targeted for assessment by the newly created measure as well as the creation of the measure itself; (iii) evaluation of the content of the FDSD among participants with FD; and (iv) preliminary evaluation of the measurement properties of the items and scores produced by the FDSD when completed by participants with FD.

Methods
=======

Concept elicitation interviews with participants
------------------------------------------------

A total of 45 face-to-face, 60 min concept elicitation interviews were conducted to identify and document the symptoms of FD from the perspective of individuals with the condition. Study participants were recruited from four sites in the United States, based on the study's inclusion and exclusion criteria ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}), and interviewed between March and October 2014. Broadly, participants were adults ≥18 years old, who met the Rome III diagnostic criteria ([@bib2]) for FD (diagnosis and subtype categorization were determined by the recruiting clinician) without other gastrointestinal disorders (e.g., active constipation, irritable bowel syndrome, or gastroesophageal reflux disease).

Approval to execute the study was received from Copernicus Group Independent Review Board on 1 November 2013 and from Mary Hitchcock Memorial Hospital on 14 March 2014. All participants provided written informed consent before participation and, once enrolled, completed a Demographic Health and Information Form. A clinician-completed Case Report Form was also used to collect clinical data. During the interviews, interviewers followed a semi-structured interview guide to elicit symptom concepts from participants. When addressing a symptom, the interviewer probed using follow-up questions in order to collect data on dimensions of the symptom, including duration, frequency, and severity. All interviews were audio-recorded (with participant consent), anonymized, and imported into ATLAS.ti, a computerized qualitative data analysis package (Berlin, Germany), to facilitate content analysis. To evaluate saturation (i.e., the point at which no new or relevant information is gained from additional interviews), concept emergence was documented across sets of successive interviews, according to established methods ([@bib11], [@bib12], [@bib13]). Unique concepts (e.g., bloating) were tabulated for frequency and mean bothersome ratings (on a scale of 0 (No bother) to 10 (Most bothersome)) were calculated for each symptom. In addition, separate from the bothersome rating exercise, participants were asked to rank the symptoms in which they would most like to see improvement with treatment.

Concept selection and preliminary *FDSD* construction
-----------------------------------------------------

The FD Working Group held a 1-day meeting with an expert panel to identify and select target measurement concepts for inclusion in the preliminary FDSD. Together with the FDA PRO Guidance ([@bib6]), the following criteria were considered when selecting potential concepts: concept's frequency of report by participants, bothersome rating (i.e., participants' level of subjective bother associated with the symptom), inclusion in the Rome III Diagnostic Criteria ([@bib2]), documentation in the empirical literature, and applicability to all participants, regardless of FD subtype. Following concept selection, the preliminary FDSD was constructed in the context of defining the following: the context of use, mode of data collection, recall period, instructions, items, and response options.

Upon creation of the preliminary measure, a translatability assessment of the FDSD was conducted by having linguistic validation experts review the tool, comment on any text or concepts that may present difficulty in future translation efforts, and provide solutions to mitigate concerns. In this regard, the following languages were included in the translatability assessment: German (Germany), Italian (Italy), Russian (Russia), Hindi (India), Japanese (Japan), French (France), Spanish (Mexico), Arabic (Egypt), Chinese (China), and Korean (Korea). In addition, an electronic implementation assessment was conducted by the Electronic Patient-Reported Outcome (ePRO) Consortium's Instrument Migration Subcommittee to determine the suitability of the preliminary FDSD for data collection on a handheld ePRO device.

Cognitive interviews
--------------------

Following the FDSD's construction and its implementation on a handheld ePRO device (LG Nexus 5 smartphone, programmed by Biomedical Systems (Maryland Heights, MO), and hereafter referred to as "device"), a total of 57 face-to-face, 60 min cognitive interviews were conducted with participants with FD in two waves, to collect qualitative data on the readability, comprehensibility, relevance, and comprehensiveness of the FDSD. Eight participants in the initial wave completed paper-based screenshots of the electronic FDSD to test preliminary wording before device programming. A second wave of 49 participants completed the FDSD on the device. All participants first completed the FDSD without interruption and then were probed in a structured manner to evaluate the readability, comprehensibility, and relevance of the FDSD. Participants in the second wave were also questioned on the usability of the FDSD on the device. All interviews were conducted in the United States between June 2015 and September 2016; due to minimal revisions to the FDSD between waves, data collected in both waves were pooled for the qualitative and quantitative analyses reported here.

To facilitate recruitment of a sample that reflects the real-world FD population ([@bib14]), those with active irritable bowel syndrome or chronic constipation were eligible to participate in the cognitive interviews. The inclusion and exclusion criteria were amended and protocol amendments were approved by the aforementioned IRBs before the start of recruitment. Participant clinical and sociodemographic data were collected using the Demographic Health and Information Form and Case Report Form. Content analysis compared participants' interpretations of the instructions, items, and response options to the developer definitions that were drafted following the initial development of the FDSD. In addition, the second wave participants' responses to questions regarding their overall opinion on the usability of the FDSD on the device were analyzed.

Preliminary evaluation of the FDSD's measurement properties
-----------------------------------------------------------

Data collected from participants' initial completion of the FDSD (i.e., the numeric responses to the FDSD provided by participants) were analyzed to gain a preliminary understanding of the performance of the items and proposed scale (i.e., total symptom) score produced by the FDSD. Specifically, using SAS version 9.4 (SAS Institute, Cary, NC), the following properties were evaluated: missingness, score distributions, floor and ceiling effects (defined as ≥25.0% of participants selecting the response that reflects the worst or best possible state, respectively), item discrimination, inter-item correlations, internal consistency reliability, and construct-related validity using known-groups methods. The cross-sectional study design, while considered sufficient for the stated research goals, precluded the ability to generate results related to other indicators of psychometric performance, including test--retest reliability and sensitivity to change.

Results
=======

Concept elicitation interviews with participants
------------------------------------------------

A total of 45 interviews were conducted ([Table 1](#tbl1){ref-type="table"}) and participants spontaneously reported 19 symptom concepts, 95.7% (*n*=18) of which were elicited in the first 75% of interviews. Within each FD subtype, a similar downward trend in the elicitation of new concepts was observed, with no new relevant concepts emerging in the last 25% of interviews, thus providing evidence that conceptual saturation was reached. The 19 identified concepts are listed in [Figure 2](#fig2){ref-type="fig"} for the full sample and in a graph ([Figure 3](#fig3){ref-type="fig"}) by FD subtype. Across all 19 symptoms, mean participant-reported bothersome ratings ranged from 4.0 to 9.0, whereas mean bothersome ratings for symptoms rated by at least two-thirds of participants each (i.e., bloating, early satiety, stomach pain, and nausea) ranged from 6.3 to 7.5. The two symptoms ranked by participants as most important to improve if an effective treatment were available were bloating and stomach pain. Based on these results, the following seven symptom concepts were identified for inclusion in the preliminary measure: stomach pain, upper abdominal burning, nausea, bloating, postprandial fullness, early satiety, and burping/belching.

Development of the preliminary FDSD
-----------------------------------

The preliminary FDSD was an eight-item measure, intended for daily administration on a handheld ePRO device, to assess symptoms of FD in the context of a clinical trial. Items 1 through 6 assessed the severity of stomach pain, upper abdominal burning, nausea, bloating, postprandial fullness, and early satiety, respectively. Items 7 and 8 assessed burping/belching in terms of the level of bother and severity, respectively. A diagram showing the location of the stomach was included at the beginning of the FDSD to instruct respondents to think only about symptoms in this area. In addition, respondents were asked to reflect over the past 24 h while responding to the FDSD and responses were scored on an 11-point numeric rating scale from 0 (no (concept)) to 10 (worst imaginable (concept)). A 24 h recall period was deemed appropriate, as the FDSD concepts of measurement can be variable both between days and within a day. The selection of an 11-point numeric rating scale is consistent with suggestions that the scale has relative advantages in minimizing missing data, patient preference, ease of recording, and ease of implementation in clinical trials ([@bib15]).

FDSD item-level scores and a Total Symptom Score (TSS) were calculated. The TSS comprised Items 1, 2, 4, 5, and 6 of the FDSD; Items 3, 7, and 8 were considered supplementary items (symptoms relevant to 68.9--73.3% of participants but not considered cardinal symptoms of FD by the expert panel) and were not included in the TSS. The FDSD TSS ranged from 0 to 50, with higher scores indicating greater symptom burden. Although some minor revisions were suggested to the FDSD following the translatability and electronic implementation assessments, it was decided that no revisions to the FDSD would be made before the cognitive interviews. Developer's definitions were agreed upon for each item to help ensure conceptual equivalence when translating the FDSD into other languages.

Cognitive interviews with participants
--------------------------------------

A total of 57 interviews were conducted with participants with FD ([Table 1](#tbl1){ref-type="table"}). Although individuals with irritable bowel syndrome or chronic constipation were eligible for participation in the cognitive interviews, very few participants with these comorbidities were recruited (≤5 for each).

Participants who provided an interpretable response interpreted the FDSD instructions (Part 1: 94.5%, *n*=52/55; Part 2: 98.2%, *n*=55/56), diagram (96.4%, *n*=54/56), response anchors (≥92.0% for each item), and recall period of the past 24 h (94.4%, *n*=51/54) as intended. The majority of participants in the first wave (62.5%, *n*=5/8) reported a preference for the recall period at the beginning of each item (i.e., "over the past 24 h..."), and all items were revised to this format for the second wave.

Overall, participants were able to read, understand, and provide meaningful responses to all eight items of the FDSD. Specifically, for Item 1 and Items 3--8, at least 81.8% of participants interpreted the item as intended. Interpretation issues included attribution of the concept to an incorrect location or item interpretations that did not align with developers' definitions. For example, when interpreting Item 2 (burning in the stomach), all but 1 of the 11 participants (21.6%) who did not interpret the item as intended were incorrectly thinking of either heartburn or burning in the throat/esophagus or chest. In addition, Item 4 (bloating) and Item 5 (stomach fullness) were not interpreted as intended by 14.3 and 14.5% of participants, respectively (*n*=8/56 and *n*=8/55). Participants who misinterpreted these items were most commonly thinking about bloating as a sensation of being full of food (without mention of air/gas), and stomach fullness as the feeling of satisfaction or contentment following completion of a meal (rather than an uncomfortable fullness).

Overall, all items of the FDSD were relevant to the target population, with participants reporting that they were currently experiencing or had experienced the symptoms assessed by the measure. For Items 1--7, at least 90.7% of participants reported experiencing the concept being evaluated by the FDSD, either within or before the 24 h recall period. For Item 8, most participants had experienced being bothered by burping/belching at some time (84.2%, *n*=48/57), but 15.8% of participants (*n*=9/57) reported never being bothered by burping/belching due to FD.

All participants who completed the FDSD on the device reported that it was easy to read the items on the screen of the device (100%, *n*=48/48) and had an overall positive opinion of using the device to complete the FDSD (100%, *n*=49/49). Median time for *FDSD* completion was 1 min 35 s (range=44 s to 6 min 43 s). Additional results regarding the usability assessment of the device are provided as [Supplementary Material](#sup1){ref-type="supplementary-material"} ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

Preliminary evaluation of measurement properties
------------------------------------------------

There were no missing data recorded for the FDSD, with 100.0% (*N*=57) of participants providing data for all items. Overall, the responses to items were well distributed among the response options for the FDSD, indicating that participants were using all levels of the ordinal response scale (see [Supplementary Table 3](#sup1){ref-type="supplementary-material"} for item distribution table). A ceiling effect (≥25.0%) was observed for Item 8 (burping/belching bother) and no items demonstrated a floor effect ([Table 2](#tbl2){ref-type="table"}). Inter-item correlations indicated that no items were capturing redundant information (Pearson's correlation *r*\<0.80, in all instances) ([@bib16], [@bib17]) ([Table 3](#tbl3){ref-type="table"}). The FDSD TSS yielded Cronbach's *α*=0.87, above the *a priori*-identified threshold (*α*≥0.70) for acceptable internal consistency reliability ([Table 2](#tbl2){ref-type="table"}), and remained above threshold following removal of each of the items composing the TSS (Items 1, 2, 4, 5, and 6). Item discrimination index analyses suggest that the FDSD items composing the TSS are able to discriminate among participants with mild/moderate FD and participants with severe FD to varying degrees ([Table 2](#tbl2){ref-type="table"}). As hypothesized, the FDSD TSS demonstrated an increasing monotonic trend across known severity groups for both participant-reported and clinician-reported FD severity (that is, TSS increased with increasing severity of FD). For participant-reported FD severity, Items 1 (stomach pain), 2 (burning in the stomach), 7 (burping/belching rating), and 8 (burping/belching bother) demonstrated an increasing monotonic trend. For clinician-reported FD severity, all items with the exception of Items 4 (bloating), 7 (burping/belching rating), and 8 (burping/belching bother) demonstrated an increasing monotonic trend across known severity groups ([Table 2](#tbl2){ref-type="table"}).

Revised FDSD and conceptual framework
-------------------------------------

The number of items in the FDSD remained unchanged following analysis of the cognitive interview data; however, revisions were made to item wording and ordering. Following the initial wave of eight cognitive interviews, the recall period for each item was moved from the end of the item to the beginning of the item, based on participant preference. In addition, the order of Item 7 (burping/belching) and Item 8 (burping/belching bother) was switched. Following the second wave of 49 cognitive interviews, modifications were made to the instructions and four items. The FDSD instructions were revised to better define the location of FD symptoms, and Item 1 (stomach pain) and Item 2 (burning in the stomach) were reversed, enabling stomach burning to be assessed directly following the diagram. Additional clarification was also added to Item 4 (bloating) and Item 5 (stomach fullness). The revised conceptual framework is shown in [Table 4](#tbl4){ref-type="table"}. No changes to the provisional scoring of the *FDSD* were made on the basis of the quantitative analyses.

Discussion
==========

The FDSD is a novel, content-valid PRO measure that is being developed according to FDA guidance recommendations. Results from the concept elicitation interviews (*N*=45) suggest that, although participants experience a number of FD-related symptoms, core symptoms of the condition are similar across both FD subtypes and FD severity levels. Using these results, in conjunction with findings from a review of the published literature and expert clinician input, the FD Working Group constructed a preliminary measure: the eight-item FDSD for implementation on a handheld ePRO device. Translatability assessment confirmed that the FDSD's instructions and items should be minimally problematic when future translation and linguistic validation activities are undertaken.

Overall, participants in cognitive interviews were able to read, understand, and provide meaningful responses to all eight items of the preliminary FDSD. Minor changes to the measure were made following both the first and second wave of cognitive interviews. Revisions were implemented to clarify the concept measured by each item and to promote improved understanding for respondents. Although these modifications were intended to improve the items in an evidence-based manner (i.e., revising based on the most frequent misinterpretation), there may be a residual number of participants who still fail to interpret the item as intended; however, further revision to the items was considered a risk to the understandability of the items by the majority of patients. With respect to the implementation of the FDSD on the device, participants with FD had, overall, a favorable opinion of using the device, demonstrating its usability within the target patient population.

The preliminary evaluation of the FDSD's measurement properties provides support for the performance of the FDSD's items and TSS in the assessment of FD symptoms. Responses were well distributed across the 11-point scale and, although a ceiling effect was observed for Item 8 (burping/belching bother) (26.3%), this is considered a supplementary item of the FDSD. It is possible that participants in the cognitive interview study experienced relatively low levels of this concept as part of their symptom experience and this is not indicative of an issue with the performance of the scores produced by the FDSD. As this item is not used to calculate the FDSD TSS, the observed ceiling effect does not have a bearing on the performance of the overall symptom score.

Item discrimination index analyses generated using participant-reported FD severity level groups suggest that the FDSD is able to discriminate among FD patients on the basis of self-reported severity. Inter-item correlations indicate that all items of the FDSD correlate positively with one another and no item pairs surpassed the *a priori* threshold (*r*\>0.80) for redundancy, suggesting that, although items of the measure are capturing related information, no items are redundant. Overall internal consistency, as calculated using Cronbach's *α* (*α*=0.87), surpassed the threshold and remained high and in the acceptable range following removal of each of the items composing the TSS (i.e., Items 1, 2, 4, 5, and 6). The known-groups approach to assessing construct validity showed that the FDSD is able to distinguish between pre-defined groups based on participant- and clinician-reported levels of FD severity.

One potential limitation to the qualitative research presented was the discrepancy between participant-reported symptoms and the categorization of participants into FD subtypes (EPS, PDS, and co-existing EPS and PDS) by recruiting clinicians. During both concept elicitation and cognitive interviews, participants categorized as EPS nonetheless reported experiencing PDS-specific symptoms (e.g., postprandial fullness and early satiety), and vice versa. Another measure, the Leuven Postprandial Distress Scale ([@bib18], [@bib19]), was recently developed based on results from focus groups and cognitive interviews in a PDS population (as identified by Rome III criteria). Similar to the FDSD, the Leuven Postprandial Distress Scale assesses bloating, postprandial fullness, and early satiety, and has been found to be content valid for both PDS and co-existing EPS and PDS subtypes in a controlled treatment trial, although these items have not been tested in a pure EPS population. Future research may focus on FD subtype identification in the PRO measure development space.

Another limitation to the research presented is the relatively small sample size used for the preliminary evaluation of the FDSD's measurement properties. Although the sample sizes used in the concept elicitation and cognitive interview activities (*N*=45 and *N*=57, respectively) are considered sufficient for qualitative analyses, a larger sample would have provided a more robust assessment of the FDSD's measurement properties. Further, it was not possible to evaluate certain psychometric properties, based on the study design of the cognitive interviews. As the FDSD was completed at only one time point, test--retest reliability could not be evaluated and because it was not completed in the context of a clinical trial, sensitivity to change could not be assessed. Convergent and divergent validity evaluations were not conducted owing to a lack of a comparison measure in the study with which to correlate the FDSD.

Future psychometric evaluations are recommended to further evaluate the score performance of the FDSD in the target patient population, including test--retest reliability and sensitivity to change, as well as score interpretation and responder definitions within the context of a treatment outcome trial. The FDSD will be submitted under the FDA's Drug Development Tool Qualification Program and the measure will be made publicly available for use to support primary endpoints in future, regulated FD clinical trials. This support will enable a pathway forward and eliminate barriers to drug development programs in a disease area characterized by unmet need.

Study Highlights
================
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![Literature-based conceptual model for functional dyspepsia symptoms ([@bib9]). BM, bowel movement; GERD, gastroesophageal reflux disease; IBS, irritable bowel syndrome; PRO, patient-reported outcome. (**a**) Concepts in Rome III criteria for FD; (**b**) concepts assessed by existing FD instruments; (**c**) concepts reported by patients in published qualitative research. This figure was originally published in Taylor *et al.* ([@bib9]).](ajg2017265f1){#fig1}

![List of functional dyspepsia signs and symptoms. \*Percentages represent frequency of participant (*N*=45) report during concept elicitation interviews † ([@bib2]).](ajg2017265f2){#fig2}

![Participant-reported functional dyspepsia concepts by subtype. \*BM, bowel movement; EPS, epigastric pain-syndrome; PDS, postprandial distress syndrome.](ajg2017265f3){#fig3}

###### Clinical and sociodemographic characteristics of participants

                                                                         Concept elicitation interviews (*N*=45)   Cognitive interviews (*N*=57)                          
  ---------------------------------------------------------------------- ----------------------------------------- ------------------------------- ---------------------- ------------------------
  *Age*                                                                                                                                                                   
   Mean, s.d. (range)                                                    46.2, 13.0 (21.0--73.5)                   42.6, 14.7 (22.1--69.8)                                
  *Sex (*n *(%))*                                                                                                                                                         
   Female                                                                32 (71.1%)                                45 (78.9%)                                             
   Male                                                                  13 (28.9%)                                12 (21.1%)                                             
  *Hispanic or Latino ethnicity (*n *(%))*                                                                                                                                
   Yes                                                                   12 (26.7%)                                13 (22.8%)                                             
   No                                                                    33 (73.3%)                                44 (77.2%)                                             
  *Race (*n *(%))*                                                                                                                                                        
   White                                                                 31 (68.9%)                                45 (78.9%)                                             
   Asian                                                                 2 (4.4%)                                  0 (0.0%)                                               
   Black or African  American                                            1 (2.2%)                                  7 (12.3%)                                              
   Native Hawaiian or other Pacific Islander                             1 (2.2%)                                  0 (0.0%)                                               
   Other[a](#t1-fn2){ref-type="fn"}                                      6 (13.3%)                                 4 (7.0%)                                               
   Not answered                                                          4 (8.9%)                                  1 (1.8%)                                               
  *Highest level of education (*n *(%))*                                                                                                                                  
   Some college or certificate program                                   11 (24.4%)                                22 (38.6%)                                             
   College or university degree (2 or 4 year)                            18 (40.0%)                                19 (33.3%)                                             
   High school diploma (or GED) or less                                  12 (26.7%)                                10 (17.5%)                                             
   Graduate degree                                                       4 (8.9%)                                  5 (8.8%)                                               
   Currently in college                                                  0 (0.0%)                                  1 (1.8%)                                               
  *Clinician-reported FD subtype (*n *(%))*[b](#t1-fn3){ref-type="fn"}                                                                                                    
   EPS                                                                   14 (31.1%)                                20 (35.1%)                                             
   PDS                                                                   14 (31.1%)                                20 (35.1%)                                             
   Co-existing EPS and PDS                                               17 (37.8%)                                17 (29.8%)                                             
  *FD severity (*n *(%))*[c](#t1-fn4){ref-type="fn"}                     *Clinician-reported*                      *Participant-reported*          *Clinician-reported*   *Participant-reported*
   Mild                                                                  11 (24.4%)                                7 (15.6%)                       17 (29.8%)             10 (17.5%)
   Moderate                                                              25 (55.6%)                                26 (57.8%)                      20 (35.1%)             34 (59.6%)
   Severe                                                                9 (20.0%)                                 12 (26.7%)                      20 (35.1%)             13 (22.8%)

EPS, epigastric pain syndrome; PDS, postprandial distress syndrome.

For concept elicitation interviews, the following responses were marked as "Other" by participants: Hispanic (*n*=6, 13.3%). For cognitive interviews, the following responses were marked as "Other" by participants: Hispanic (*n*=2, 3.5%), Mexican/Puerto Rican (*n*=1, 1.8%), and Spanish (*n*=1, 1.8%).

As determined by the Rome III Diagnostic Criteria([@bib2]) at time of participant screening.

Determined by participants' responses on the Demographic Health and Information Form and clinicians' responses on the Case Report Form.

###### FDSD acceptability, item discrimination, reliability, and known-groups analysis results (*N*=57)

  FDSD item[a](#t2-fn2){ref-type="fn"}   Ceiling[b](#t2-fn3){ref-type="fn"} *n* (%)   Floor[b](#t2-fn3){ref-type="fn"} *n* (%)   Item discrimination index[c](#t2-fn4){ref-type="fn"}   Cronbach's *α* (TSS; or on item removal)   Known groups (participant-reported severity)[d](#t2-fn5){ref-type="fn"} Mean (s.d.)   Known groups (clinician-reported severity)[e](#t2-fn6){ref-type="fn"} Mean (s.d.)
  -------------------------------------- -------------------------------------------- ------------------------------------------ ------------------------------------------------------ ------------------------------------------ ------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  TSS (0--50)                            ---                                          ---                                        ---                                                    0.87                                       Mild: 23.4 (9.86) Moderate: 24.6 (10.57) Severe: 30.8 (14.90)                         Mild: 20.1 (9.54) Moderate: 27.4 (11.97) Severe: 29.3 (11.79)
  1\. Stomach pain (0--10)               3 (5.3%)                                     3 (5.3%)                                   0.40                                                   0.84                                       Mild: 4.1 (2.56) Moderate: 4.5 (2.31) Severe: 6.5 (2.99)                              Mild: 3.8 (2.28) Moderate: 4.9 (2.76) Severe: 5.9 (2.51)
  2\. Burning in the stomach (0--10)     7 (12.3%)                                    1 (1.8%)                                   0.38                                                   0.89                                       Mild: 2.9 (2.69) Moderate: 4.6 (2.09) Severe: 5.8 (3.41)                              Mild: 3.3 (2.44) Moderate: 4.9 (1.87) Severe: 5.4 (3.20)
  3\. Nausea (0--10)                     13 (22.8%)                                   2 (3.5%)                                   0.08                                                   ---                                        Mild: 3.3 (2.16) Moderate: 4.1 (3.31) Severe: 4.1 (3.38)                              Mild: 3.3 (3.12) Moderate: 4.1 (3.19) Severe: 4.4 (3.13)
  4\. Bloating (0--10)                   5 (8.8%)                                     6 (10.5%)                                  0.22                                                   0.84                                       Mild: 5.4 (2.59) Moderate: 5.2 (2.77) Severe: 6.0 (3.87)                              Mild: 4.4 (2.47) Moderate: 6.2 (2.73) Severe: 5.6 (3.47)
  5\. Stomach fullness (0--10)           3 (5.3%)                                     4 (7.0%)                                   0.21                                                   0.84                                       Mild: 6.0 (2.31) Moderate: 5.6 (2.81) Severe: 6.5 (3.31)                              Mild: 4.9 (2.18) Moderate: 5.9 (3.23) Severe: 6.6 (2.78)
  6\. Early satiety (0--10)              8 (14.0%)                                    3 (5.3%)                                   0.25                                                   0.83                                       Mild: 5.0 (2.75) Moderate: 4.8 (3.02) Severe: 6.0 (3.98)                              Mild: 3.8 (2.61) Moderate: 5.6 (3.24) Severe: 5.8 (3.41)
  7\. Burping/belching rating (0--10)    4 (7.0%)                                     4 (7.0%)                                   0.23                                                   ---                                        Mild: 3.9 (2.47) Moderate: 4.7 (2.49) Severe: 5.3 (3.82)                              Mild: 3.3 (2.44) Moderate: 5.8 (2.36) Severe: 4.9 (3.15)
  8\. Burping/belching bother (0--10)    15 (26.3%)                                   3 (5.3%)                                   0.13                                                   ---                                        Mild: 3.4 (2.80) Moderate: 4.1 (3.17) Severe: 4.7 (3.97)                              Mild: 2.8 (2.79) Moderate: 4.8 (3.19) Severe: 4.7 (3.56)

CRF, Case Report Form; DHIF, Demographic Health and Information Form; FD, functional dyspepsia; FDSD, Functional Dyspepsia Symptom Diary; TSS, Total Symptom Score.

FDSD items are scored on an 11-point numeric rating scale from 0 (no (concept)) to 10 (worst imaginable (concept)).

Floor and ceiling effects are represented by the percent of participants responding to the worst possible state/best possible state; in this instance, floor effect refers to a high percentage (≥25.0%) of participants selecting the score reflecting a state which cannot get any worse (i.e., 10, worst imaginable (concept)) and ceiling effect refers to a high percentage (≥25.0%) of participants selecting the score reflecting a state, which cannot get any better (i.e., 0, no (concept))([@bib20], [@bib21], [@bib22]).

Item discrimination index=proportion endorsed for severe group---proportion endorsed for mild/moderate group. The item discrimination index assesses the extent to which item responses accurately capture genuine patient experiences and are represented on a scale from 1 to −1, where negative or zero indices characterize poorly performing items and positive indices characterize well-performing items. Indices were evaluated using the following criterion: ≤0.20=poor performance, 0.21 to 0.29=moderate performance, 0.30 to 0.39=good performance, ≥0.40=excellent performance([@bib23]).

Participant-reported FD severity based on response in DHIF: mild *n*=10; moderate *n*=34; severe *n*=13.

Clinician-reported FD severity based on response in CRF: mild *n*=17; moderate *n*=20; severe *n*=20.

###### Inter-item Pearson's correlations for the FDSD items (*N*=57)

  FDSD item\*                   FDSD item number                                             
  ----------------------------- ------------------ ------ ------ ------ ------ ------ ------ ------
  1\. Stomach pain              1.00               ---    ---    ---    ---    ---    ---    ---
  2\. Burning in the stomach    0.66               1.00   ---    ---    ---    ---    ---    ---
  3\. Nausea                    0.48               0.40   1.00   ---    ---    ---    ---    ---
  4\. Bloating                  0.60               0.40   0.49   1.00   ---    ---    ---    ---
  5\. Stomach fullness          0.61               0.34   0.62   0.69   1.00   ---    ---    ---
  6\. Early satiety             0.60               0.38   0.59   0.74   0.77   1.00   ---    ---
  7\. Burping/belching rating   0.43               0.41   0.55   0.52   0.35   0.38   1.00   ---
  8\. Burping/belching bother   0.30               0.34   0.43   0.45   0.21   0.36   0.78   1.00

FDSD, Functional Dyspepsia Symptom Diary.

\*FDSD items are scored on an 11-point numeric rating scale from 0 (no (concept)) to 10 (worst imaginable (concept)). Pearson's correlation coefficients *r*\>0.80 indicate items are capturing potentially redundant information ([@bib24]).

###### Conceptual framework of the FDSD TSS[a](#t4-fn2){ref-type="fn"}

  Domain                                  Concept               *FDSD* Item
  --------------------------- --- ------------------------ --- -------------
  FD symptom severity (TSS)    →   Burning in the stomach   →     Item 1
                                        Stomach pain        →     Item 2
                                          Bloating          →     Item 4
                                   Postprandial fullness    →     Item 5
                                       Early satiety        →     Item 6

FD, functional dyspepsia; FDSD, Functional Dyspepsia Symptom Diary; TSS, Total Symptom Score.

Item 3 (nausea), Item 7 (burping/belching rating), and Item 8 (burping/belching bother) are included in the FDSD; however, because they are considered supplementary assessments and are not anticipated to be included in the TSS or used in trial endpoints, they are not included in the conceptual framework (they will instead be scored as individual items).
